<sup>177</sup>Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 35853739.
- Also identified by DOI 10.2967/jnumed.122.264293.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate feasibility, additional benefit and toxicity of treatment extension of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). <b>Methods:</b> From 208 patients treated with <sup>177</sup>Lu-PSMA every 6-8 weeks, 26 patients who had not progressed and not experienced ≥grade 3 toxicity after 6 cycles continued to receive <sup>177</sup>Lu-PSMA until disease progression or complete remission or removal from treatment for toxicity or patient preference. Response rates, the additional benefit of treatment extension, and toxicity were assessed. <b>Results:</b> During treatment extension (up to 13 cycles), 50% of patients achieved an additional PSA decline (-52%±34%, range 1% to 100%), with 8% of patients receiving congruent PSA-based and imaging-based complete response. Median PFS was 450 days. Acute toxicity, including myelosuppression, was mild (≤ grade 2). Xerostomia and chronic kidney disease became more common with repetitive dosing. <b>Conclusion:</b> Extension of <sup>177</sup>Lu-PSMA treatment is feasible and effective in mCRPC.